Accéder directement au contenu Accéder directement à la navigation
Nouvelle interface
Article dans une revue

Invasive pulmonary aspergillosis among intubated patients with SARS-CoV-2 or influenza pneumonia: a European multicenter comparative cohort study

Anahita Rouzé 1, 2 Elise Lemaitre 2 Ignacio Martin-Loeches Pedro Povoa Emili Diaz Rémy Nyga 3 Antoni Torres Matthieu Metzelard Damien Du Cheyron Fabien Lambiotte 4 Fabienne Tamion 5 Marie Labruyere 6 Claire Boulle Geronimi 7 Charles-Edouard Luyt 8 Martine Nyunga 9 Olivier Pouly 10 Arnaud W Thille 11 Bruno Megarbane 12, 13 Anastasia Saade 14 Eleni Magira Jean-François Llitjos 15 Iliana Ioannidou Alexandre Pierre 16 Jean Reignier 17 Denis Garot 18 Louis Kreitmann 19 Jean-Luc Baudel 20 Guillaume Voiriot 21 Gaëtan Plantefeve 22 Elise Morawiec 23, 24 Pierre Asfar 25 Alexandre Boyer 26 Armand Mekontso-Dessap 27, 28 Demosthenes Makris Christophe Vinsonneau 29 Pierre-Edouard Floch 30 Clémence Marois 23, 31 Adrian Ceccato Antonio Artigas Alexandre Gaudet 32 David Nora Marjorie Cornu 1, 2 Alain Duhamel 2 Julien Labreuche 2 Saad Nseir 2, 1 Julien Maizel 33, 34 
Abstract : Background Recent multicenter studies identified COVID-19 as a risk factor for invasive pulmonary aspergillosis (IPA). However, no large multicenter study has compared the incidence of IPA between COVID-19 and influenza patients. Objectives To determine the incidence of putative IPA in critically ill SARS-CoV-2 patients, compared with influenza patients. Methods This study was a planned ancillary analysis of the coVAPid multicenter retrospective European cohort. Consecutive adult patients requiring invasive mechanical ventilation for > 48 h for SARS-CoV-2 pneumonia or influenza pneumonia were included. The 28-day cumulative incidence of putative IPA, based on Blot definition, was the primary outcome. IPA incidence was estimated using the Kalbfleisch and Prentice method, considering extubation (dead or alive) within 28 days as competing event. Results A total of 1047 patients were included (566 in the SARS-CoV-2 group and 481 in the influenza group). The incidence of putative IPA was lower in SARS-CoV-2 pneumonia group (14, 2.5%) than in influenza pneumonia group (29, 6%), adjusted cause-specific hazard ratio (cHR) 3.29 (95% CI 1.53–7.02, p = 0.0006). When putative IPA and Aspergillus respiratory tract colonization were combined, the incidence was also significantly lower in the SARS-CoV-2 group, as compared to influenza group (4.1% vs. 10.2%), adjusted cHR 3.21 (95% CI 1.88–5.46, p < 0.0001). In the whole study population, putative IPA was associated with significant increase in 28-day mortality rate, and length of ICU stay, compared with colonized patients, or those with no IPA or Aspergillus colonization. Conclusions Overall, the incidence of putative IPA was low. Its incidence was significantly lower in patients with SARS-CoV-2 pneumonia than in those with influenza pneumonia. Clinical trial registration The study was registered at ClinicalTrials.gov, number NCT04359693 .
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal-u-picardie.archives-ouvertes.fr/hal-03820642
Contributeur : Mélanie Bouchard Connectez-vous pour contacter le contributeur
Soumis le : vendredi 18 novembre 2022 - 15:55:39
Dernière modification le : samedi 26 novembre 2022 - 04:06:05

Fichier

s13054-021-03874-1.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Citation

Anahita Rouzé, Elise Lemaitre, Ignacio Martin-Loeches, Pedro Povoa, Emili Diaz, et al.. Invasive pulmonary aspergillosis among intubated patients with SARS-CoV-2 or influenza pneumonia: a European multicenter comparative cohort study. Critical Care, 2022, 26 (1), pp.11. ⟨10.1186/s13054-021-03874-1⟩. ⟨hal-03820642⟩

Partager

Métriques

Consultations de la notice

0

Téléchargements de fichiers

0